ADL 5859
Alternative Names: ADL-5859; PF-04856880; PF-4856880Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Adolor Corporation
- Developer Adolor Corporation; Pfizer
- Class Opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Opioid delta receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dental pain; Inflammatory pain; Neuropathic pain
Most Recent Events
- 18 Jun 2010 Efficacy and adverse events data from a phase IIa trial in Inflammatory pain (osteoarthritis of knee) released by (Adolor Corporation)
- 30 Oct 2009 Adolor and Pfizer initiate a phase IIa proof-of-concept trial for patients with osteoarthritis in the US
- 15 Dec 2007 Phase-II clinical trials in Neuropathic pain in USA (PO)